Posted by Michael Wonder on 18 Aug 2021
Abiraterone acetate for treating newly diagnosed high-risk hormone sensitive metastatic prostate cancer
18 August 2021 - NICE has published final guidance on the use of Zytiga in newly diagnosed patients following an appeal.
Abiraterone acetate, when used in combination with prednisone or prednisolone and androgen deprivation therapy is not recommended for the treatment of adults with newly diagnosed high-risk hormone-sensitive metastatic prostate cancer.
